Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia

International Journal of Urology

Volumn 14, Issue 10, 2007, Pages 946-951

  Kang, Kyung K ^a,c   Kim, Ju M ^a   Yu, Jae Y ^a   Ahn, Byoung O ^a   Yoo, Moohi ^a   Kim, Young C ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Korean Sexual and Men's Health Center   (South Korea)

^c NONE   (South Korea)

Author keywords

Benign prostatic hyperplasia; DA 8159; Intraurethral pressure; Lower urinary tract symptoms; Phosphodiesterase 5 inhibitor

Indexed keywords

ESTRADIOL; PHOSPHODIESTERASE V INHIBITOR; STEROID HORMONE; TESTOSTERONE; UDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROSTIMULATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE CONTRACTILITY; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RAT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; URETHRA;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; PRESSURE; PROSTATE; PROSTATIC HYPERPLASIA; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; URETHRA;

EID: 34548795965     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01874.x     Document Type: Article

References (29)

1. Hansen BL. Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur. Urol. 2004 46 : 229 34.
2. Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F, Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J. Urol. 1995 153 : 669 73.
3. Bennett BC, Kruse MN, Roppolo JR, Flood HD, Fraser M, de Groat WC. Neural control of urethral outlet activity in vivo: role of nitric oxide. J. Urol. 1995 153 : 2004 9.
4. Kawahara T. Experimental studies on effect on nitric oxide on the internal urethral relaxation in anesthetized rats. Nippon Hinyokika Gakkai Zasshi 1994 85 : 1124 30.
5. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995 45 : 440 6.
6. Yoshida M, Akaike T, Inadome A et al. The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. Eur. J. Pharmacol. 1998 357 : 213 19.
7. Stothers L, Laher I, Christ GT. A review of the L-arginine - nitric oxide - guanylate cyclase pathway as a mediator of lower urinary tract physiology and symptoms. Can. J. Urol. 2003 10 : 1971 80.
8. Persson K, Alm P, Johansson K, Larsson B, Andersson KE. Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects. Br. J. Pharmacol. 1993 110 : 521 30.
9. Ehren I, Iversen H, Jansson O, Adolfsson J, Wiklund NP. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 1994 44 : 683 7.
10. Dokita S, Smith SD, Nishimoto T, Wheeler MA, Weiss RM. Involvement of nitric oxide and cyclic FMP in rabbit urethral relaxation. Eur. J. Pharmcol. 1994 266 : 269 75.
11. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002 90 : 836 9.
12. Martinez Caballero S, Carricajo Fernandez C, Perez-Fernandez R. Effect of an integral suspension of Lepidium latifolium on prostate hyperplasia in rats. Fitoterapia 2004 75 : 187 91.
13. Kontani H, Shiraoya C. Method for simultaneous recording of the prostatic contractile and urethral pressure responses in anesthetized rats and the effects of tamsulosin. Jpn. J. Pharmacol. 2002 90 : 281 90.
14. Kontani H, Shiraoya C. Sex differences in urethral pressure response to electrical stimulation of the hypogastric nerves in rats. J. Urol. 2000 163 : 1364 8.
15. Murakoshi M, Inada R, Makino M et al. Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations. Acta Pathol. Jpn. 1990 40 : 871 9.
16. Murakoshi M, Tagawa M, Inada R, Suzuki M. Effects of testosterone, and testosterone plus estrogen, in the castrated rat ventral prostate - histopathological and immunocytochemical studies. Tokai J. Exp. Clin. Med. 1992 17 : 133 7.
17. Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988 12 : 271 86.
18. Murakoshi M, Tagawa M, Inada R, Suzuki M, Mizokami A, Watanabe K. Inhibition of steroid-induced prostatic hyperplasia in rats by treatment with anti-androgen (TZP-4238). Endocr. J. 1993 40 : 479 88.
19. Persson K, Andersson KE. Non-adrenergic, non-cholinergic relaxation and levels of cyclic nucleotides in rabbit lower urinary tract. Eur. J. Pharmacol. 1994 268 : 159 67.
20. Dokita S, Morgan WR, Wheeler MA, Yoshida M, Latifpour J, Weiss RM. NG-nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation in rabbit urethral smooth muscle. Life Sci. 1991 48 : 2429 36.
21. Doh H, Shin CY, Son M et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch. Pharm. Res. 2002 25 : 873 8.
22. Choi SM, Kim JE, Kang KK. Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in SHR-SP. Life Sci. 2006 78 : 1211 16.
23. Kang KK, Yu JY, Yoo M, Kwon JW. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int. J. Impot. Res. 2005 17 : 409 16.
24. Ying J, Yao D, Jiang Y, Ren X, Xu M. The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004 10 : 681 3.
25. Hopps CV, Mulhall JP. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). J. Urol. 2003 169 (Suppl 4 375.
26. Roehrborn CG. Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitor. Rev. Urol. 2004 6 : 121 7.
27. Bahng MY, Kang KK, Ahn BO et al. Tolerance and pharmacokinetics of single-dose DA-8159 in healthy male. Int. J. Impot. Res. 2002; 14(S3): S101.
28. Amakye D, Ward J, Bryson S, Han K. DA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjects. Clin. Pharmacol. Ther. 2004 75 : 86.
29. Padma-Nathan H, Paick JS, Ahn BO, Kang KK, Bahng MY, Kim WB. Phase 1, double-blind, placebo-controlled study in healthy male subjects to investigate the safety, tolerability, and pharmacokinetics of DA-8159. J. Urol. 2004 171 (4 S234.